Prognostic Scores for Predicting Recurrence in Patients with Differentiated Thyroid Cancer

  • Somboonporn, Charoonsak (Department of Radiology, Faculty of Medicine, Khon Kaen University)
  • Published : 2016.05.01


Background: Differentiated thyroid cancer (DTC) is a cancer group that shares molecular and cellular origin but shows different clinical courses and prognoses. Several prognostic factors have been reported for predicting recurrence for individual patients. This literature review aimed to evaluate prognostic scores for predicting recurrence of DTC. Materials and Methods: A search of the MEDLINE database for articles published until December 2015 was carried out using the terms "thyroid neoplasms AND (recurrent OR persistent) AND (score OR model OR nomogram)". Studies were eligible for review if they indicated the development of prognostic scoring models, derived from a group of independent prognostic factors, in predicting disease recurrence in DTC patients. Results: Of the 308 articles obtained, five were eligible for evaluation. Two scoring models were developed for DTC including both papillary and follicular carcinoma, one for papillary carcinoma, and the other two for papillary microcarcinoma. The number of patients included in the score development cohort ranged from 59 to 1,669. The number of evaluated potential prognostic factors ranged from 4 to 25. Tumor-related factors were the most common factors included in the final scores, with cervical lymph node metastases being the most common. Only two studies showed internal validation of the derived score. Conclusions: There is a paucity of prognostic scores for predicting disease recurrence in patients with DTC, in particular for follicular thyroid carcinoma. Several limitations of the created scores were found. Performance of the scores has not been adequately studied. Comprehensive validation in multiple cohorts is recommended before widespread use.


Thyroid neoplasms;recurrence;prognosis;prognostic scores


Supported by : Khon Kaen University


  1. Buffet C, Golmard JL, Hoang C, et al (2012). Scoring system for predicting recurrences in patients with papillary thyroid microcarcinoma. Eur J Endocrinol, 167, 267-75.
  2. Fernandez IJ, Piccin O, Sciascia S, et al (2013). Clinical significance of BRAF mutation in thyroid papillary cancer. Otolaryngo Head and Neck Surg, 148, 919-25.
  3. Gospodarowicz MK, O'Sullivan B, Koh ES (2006). Prognostic factors: principles and applications. In: 'Prognostic factors in cancer. 3rd ed', Eds Gospodarowicz MK, O'Sullivan B, Sobin LH. John Wiley & Sons, New Jersey, 23-38.
  4. Guyatt G (2006). Determining prognosis and creating clinical decision rules. In 'Clinical epidemiology: how to do clinical practice research.3rd ed', Eds Haynes RB, Sackett DL, Guyatt G, et al. Lippincott Williams & Wilkins, Philadelphia, 323-55.
  5. Hasbek Z, Turgut B, Kilicli F, Altuntas EE, Yucel B (2014). Importance of postoperative stimulated Tg level at the time of 131I ablation therapy for differentiated thyroid cancer. Asian Pac J Cancer Prev, 15, 2523-7.
  6. Haugen BR, Alexander EK, Bible KC, et al (2016). 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 26, 1-133.
  7. Hundahl SA, Flemming ID, Fremgen AM, Menck HR (1998). A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer, 83, 2638-48.<2638::AID-CNCR31>3.0.CO;2-1
  8. Ito Y, Kudo T, Kihara M, et al (2012). Prognosis of low-risk papillary thyroid carcinoma patients: its relationship with the size of primary tumors. Endocr J, 59, 119-25.
  9. Kim SJ, Lee KE, Myong JP, et al (2012). BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg, 36, 310-7.
  10. Kim KM, Park JB, Bae KS, et al (2013). Clinical prognostic index for recurrence of papillary thyroid carcinoma including intraoperative findings. Endocr J, 60, 291-7.
  11. Kim WY, Kim HY, Son GS, Bae JW, Lee JB (2014). Clinicopathological, immunohistochemical factors and recurrence associated with extrathyroidal extension in papillary thyroid microcarcinoma. J Cancer Res Ther, 10, 50-5.
  12. Lee J, Song Y, Soh EY (2014). Prognostic significance of the number of metastatic lymph nodes to stratify the risk of recurrence. World J Surg, 38, 858-62.
  13. Mazzaferri EL, Kloos RT (2001). Current approaches to primary therapy of papillary and follicular thyroid cancer. J Clin Endocrinol Metab, 86, 1447-63.
  14. Niemeier LA, Kuffner Akatsu H, Song C, et al (2012). A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer, 118, 2068-77.
  15. Onitilo AA, Engel JM, Lundgren CI, et al (2009). Simplifying the TNM system for clinical use in differentiated thyroid cancer. J Clin Oncol, 27, 1872-8.
  16. Pencina MJ, D'Agostino RB (2004). Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med, 23, 2109-23.
  17. Qu N, Zhang L, Ji QH, et al (2014). Number of tumor foci predicts prognosis in papillary thyroid cancer. BMC Cancer, 14, 914.
  18. Schneider DF, Mazeh H, Chen H, Sippel RS (2013). Lymph node ratio predicts recurrence in papillary thyroid cancer. Oncologist, 18, 157-62.
  19. Vergouwe Y, Steyerberg EW, Eijkemans MJ, Habbema JD (2005). Substantial effective sample sizes were required for external validation studies of predictive logistic regression models, J Clin Epidemiol, 58, 475-83.
  20. Welsch M, Abeln M, Zaplatnikov K, et al (2007). Multiparameter scoring system for the prognosis of differentiated thyroid cancer. Nuklearmedizin, 46, 257-62.
  21. Xing M, AlzahraniAS, Carson KA, et al (2015). Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol, 33, 42-50.